Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

BridGene Biosciences

Request full access

Biotechnology company using cutting-edge chemoproteomic technology to discover and develop small molecules

San Jose, United StatesFounded 2018Biotech & Life Sciences

About BridGene Biosciences

BridGene Biosciences, Inc. is a biotechnology company based in Sunnyvale, CA, specializing in the discovery of novel drug targets and the development of new therapeutics for unmet medical needs. The company employs a proprietary chemoproteomic platform called IMTAC™ to develop covalent drugs for high-value, hard-to-drug targets, including those involving protein-protein interactions or shallow binding pockets. This platform integrates advanced technologies such as covalent chemistry, chemical proteomics, and quantitative mass spectrometry. BridGene also utilizes a Target-Oriented Discovery approach, leveraging its industry-leading expertise to identify and develop new drug candidates.

The company primarily serves pharmaceutical and biotechnology firms looking for innovative solutions to complex medical challenges. Operating in the highly competitive biotechnology market, BridGene's business model focuses on research and development, partnering with other companies for drug development, and potentially licensing its proprietary technologies. Revenue is generated through these partnerships, licensing agreements, and milestone payments.

Source: Dealroom company data

At a glance

Status
Operational
Employees
31
Open positions
None listed
Dealroom signal
83.5/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Oct 2025 $28M $193M ShenZhen GTJA Investment Group · Proxima Ventures · Lapam Capital · Grains Valley Venture Capital ↗
SERIES BOther financing Jul 2022 $39M $154M Junson Capital · Dyee Capital · Lapam Capital ↗
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

BridGene Biosciences website traffic

Latest recorded traffic for BridGene Biosciences is 2.5K monthly website visits, up 19% over the last three months. BridGene Biosciences's team grew 47.6% over the past year.

Latest monthly visits2.5K 3-month web change+19% 1-year team growth+47.6%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

BridGene Biosciences in the San Jose ecosystem

Live from Dealroom

The BridGene Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A7 investors entered at this stage

  • Lapam Capital
  • Junson Capital
  • Dyee Capital
  • Bayland Capital
  • ShenZhen GTJA Investment Group
  • Proxima Ventures
  • Grains Valley Venture Capital

Other known investors3 additional known investors

  • Kaitai Capital
  • Takeda
  • University of Southern California
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See BridGene Biosciences’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.